PUBLIC COMPANY
save$CAPRCAPRICOR THERAPEUTICS, INC.
$CAPR9.0000+4.65%San Diego, CA, USupdated 10d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Open-label Extension of the HOPE-2 Trial
- phase3A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
- phase2A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
- phase2Intravenous Infusion of CAP-1002 in Patients With COVID-19
- phase2HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
- phase2Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)
- phase2Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
🐶 Hiring Signal
Where CAPRICOR THERAPEUTICS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaRare Disease 12Cardiovascular 1
News
- Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapyLess than two weeks away from a highly anticipated FDA ruling on its cell therapy for Duchenne muscular dystrophy, Capricor Therapeutics has reported increased investment in its San Diego plant to…biospace · 5d ago
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 6d ago
- ‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma banSince his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and C…biospace · 1mo ago
- Capricor investor calls for change as company awaits decision on Duchenne candidateKaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and capital-preservation plan.” The biotech recently put all other pipeline work…biospace · 2mo ago
- UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharmaUniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by R…biospace · 3mo ago
- STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drugAhead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.stat · 3mo ago
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that